Enteric Coated Diazoxide Formulation for Prader-Willi Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral formulations of diazoxide for treating conditions like Prader-Willi Syndrome and Smith-Magenis syndrome are limited by adverse side effects such as dyspepsia, nausea, and hyperglycemia, which restrict their utility, especially in obese patients, and do not effectively manage hyperphagia and body composition.
Innovation Solution
Development of bioavailable pharmaceutical formulations of KATP channel openers, optionally in combination with growth hormone, that specifically target SUR1/Kir6.2 potassium channels, inhibit glucose-induced insulin release, and are designed for controlled release to minimize side effects and enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current oral formulations of diazoxide are used to treat Prader-Willi Syndrome and Smith-Magenis syndrome, then some therapeutic effect is achieved, but adverse side effects such as dyspepsia, nausea, and hyperglycemia occur which restrict utility
Solution Approach 1:
The patent applies preliminary action by using enteric coating technology to pre-protect the diazoxide formulation before administration. The enteric coating is designed to resist gastric acid and prevent drug release in the stomach, ensuring the drug is delivered intact to the intestine where it can be absorbed. This preliminary protective measure prevents the adverse gastrointestinal effects that would otherwise occur with direct stomach exposure to the drug.
Solution Approach 2:
The enteric coating acts as an intermediary between the diazoxide drug and the gastrointestinal tract. This intermediate layer protects the stomach from the drug's harmful effects while still allowing the drug to reach its target site in the intestine for therapeutic action. The coating material serves as a mediator that enables drug delivery without direct harmful interaction with gastric tissues.
2Productivity
If higher doses of diazoxide are administered to manage hyperphagia and body composition, then therapeutic outcomes improve, but adverse side effects increase
Solution Approach 1:
The patent applies local quality by designing the drug delivery system to release diazoxide specifically at the intestinal level rather than throughout the entire gastrointestinal tract. The enteric coating is engineered with specific properties that allow it to remain intact in the acidic stomach environment but dissolve at the higher pH of the intestine. This localized release approach enables effective dosing without proportionally increasing systemic side effects.
Solution Approach 2:
The patent utilizes parameter changes by exploiting the pH difference between the stomach and intestine. The enteric coating is designed to withstand low pH in the stomach but dissolve at the higher pH encountered in the intestinal environment. This parameter-based release mechanism allows the drug to be delivered at therapeutic doses while minimizing exposure of sensitive gastric tissues to the drug, thereby reducing dose-dependent side effects.
3Speed
If diazoxide is released rapidly after oral administration, then quick therapeutic effect is achieved, but gastrointestinal adverse effects are intensified
Solution Approach 1:
The patent applies segmentation by dividing the drug delivery process into distinct stages: (1) protection stage in the stomach where the enteric coating prevents drug release, and (2) release stage in the intestine where the coating dissolves and drug is delivered. This segmentation of the delivery pathway allows the drug to bypass the harmful gastric environment and release quickly at the target site, achieving both rapid onset of action and reduced gastrointestinal side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations effectively increase lean body mass and reduce hyperphagia and body fat in subjects with Prader-Willi Syndrome and Smith-Magenis syndrome, with reduced adverse effects and improved patient compliance through sustained release mechanisms.
Implementation Method 1
KATP channel openers (PCOs or KCOs) are a structurally diverse group of compounds with no apparent common pharmacophore linking their ability to antagonize the inhibition of KATP channels by intracellular nucleotides
Implementation Method 2
This promotes K+ efflux and cell hyperpolarization, thereby preventing voltage-operated Ca2+ channels (VOCs) from opening
Implementation Method 3
Development of bioavailable pharmaceutical formulations of KATP channel openers, optionally in combination with growth hormone, that specifically target SUR1/Kir6.2 potassium channels, inhibit glucose-induced insulin release, and are designed for controlled release to minimize side effects and enhance therapeutic efficacy
Data Source
AI summary
Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.